Biohaven stock remains under pressure after FDA partial hold on opakalim epilepsy program
Biohaven’s opakalim program faces an FDA partial hold over a rodent metabolite, while a fully enrolled pivotal epilepsy study remains on track.
Pharma & Biotech
Pharma & Biotech
SK Biopharmaceuticals bets up to $795m on Biohaven’s opakalim before pivotal data
SK Biopharmaceuticals is acquiring worldwide rights to opakalim and Biohaven’s Kv7 platform, providing $400 million in near-term cash and assuming additional obligations while pivotal RISE3 data remain due in the second half of 2026.